Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

In vitro susceptibility profile of Plasmodium falciparum clinical isolates from Ghana to antimalarial drugs and polymorphisms in resistance markers

Frontiers in Cellular and Infection Microbiology(2022)10.3389/fcimb.2022.1015957Source: DataRank Database

In vitro susceptibility profile of Plasmodium falciparum clinical isolates from Ghana to antimalarial drugs and polymorphisms in resistance markers is a research paper published in Frontiers in Cellular and Infection Microbiology (2022). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 1.74)OA: goldTopics (59)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Xinxin Li ORCID,Qi Yang ORCID,Longcan Zhou,Mengxi Duan,Maohua Pan

Live enrichment

PubMed:36310880 PMC:PMC9614232 OpenAlex:https://openalex.org/W4306160248

NIAID NIH HHS

Grant: U19 AI089672

National Institutes of Health

Grant: 2U19AI089672-08

Southeast Asia Malaria Research Center

FWCI

1.74

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fcimb.2022.1015957/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fcimb.2022.1015957/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fcimb.2022.1015957/full

journalhttps://doi.org/10.3389/fcimb.2022.1015957

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36310880

Fields of Study

Malaria Research and ControlDrug-Induced Hepatotoxicity and ProtectionTravel-related health issues03 medical and health sciences0302 clinical medicineHumansAntimalarialsPlasmodium falciparumPyrimethamineMalaria, FalciparumGhanaArtemetherArtemether, Lumefantrine Drug CombinationChloroquineLumefantrineProtozoan Proteins

MeSH Terms

ArtemetherArtemether, Lumefantrine Drug CombinationLumefantrineAntimalarialsChloroquineGhanaHumansPlasmodium falciparumPyrimethamineProtozoan ProteinsMalaria, Falciparum

Keywords

PiperaquineMefloquineLumefantrineDihydroartemisininArtemetherPlasmodium falciparumChloroquineArtesunatePyrimethamineMalariaDrug resistanceArtemisininPharmacologyBiologyVirologyQuinineMedicineMicrobiologyImmunologyGenetic polymorphismMalaria ParasiteIn Vitro AssayWest AfricaRing Survival AssayArtemether, Lumefantrine Drug CombinationProtozoan ProteinsGhanaQR1-502AntimalarialsCellular and Infection MicrobiologyHumansMalaria, Falciparum

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

In vitro susceptibility profile of Plasmodium falciparum clinical isolates from Ghana to antimalarial drugs and polymorphisms in resistance markers

FAIR Checklist

Authors (20)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)